BTNL9 and urinary bladder neoplasm: Furthermore, functional investigations unveiled that bladder tumor cells could be sensitized to Vδ2 T-cell recognition by using either amino bisphosphonate drugs (eg, Zoledronate) or agonistic α-BTN3 antibody.11 12 Even though PAgs derived from BCG extract are known to promote Vδ2 T-cell function,14 we further demonstrated that BCG-infected bladder tumor cell lines can activate cytolytic function and cytokine production of Vδ2 T cells.